Skip to main content
Premium Trial:

Request an Annual Quote

GeneGo Nets SBIR Grant from NCI

NEW YORK (GenomeWeb News) – GeneGo said today that it plans to use a Phase I Small Business Innovation Research grant from the National Cancer Institute to develop cancer data analysis software in a collaboration with the Dana-Farber Cancer Institute.
GeneGo said it is developing a system called MetaMiner that will be tailored for biologists, clinicians, and chemists involved in cancer research. The software will combine pathway and network analysis tools, serve as a data repository, and include certain statistical tools.
“We need to understand in a database structure the causal relationships between the involved pathways and the dynamics of pathway activation during tumorigenesis,” GeneGo CEO Yuri Nikolsky said in a statement.
Kornelia Polyak, an associate professor at Dana-Farber involved in the research, said that the effort will focus on development of pathway-based tools to integrate different types of data including somatic mutations, high copy number genes, epigenetics, gene expression, proteomics, and metabolomics.
Genego has received previous SBIR funding from the NCI for another cancer-centered collaboration with Mayo Clinic involving the company’s MetaCore software.
According to an NIH grants database, the one-year SBIR announced today is worth $200,000.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.